These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19687764)

  • 1. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
    Uhm JE; Park BB; Ahn MJ; Lee J; Ahn JS; Kim SW; Kim HT; Lee JS; Kang JH; Cho JY; Song HS; Park SH; Sohn CH; Shin SW; Choi JH; Park K
    J Thorac Oncol; 2009 Sep; 4(9):1136-43. PubMed ID: 19687764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
    Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
    BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
    Huang Y; Zhang L; Shi Y; Ma S; Liao M; Bai C; Zhang Q; Wang C; Luo F; Yu S; Qin S; Zhi X; Zhou C
    Jpn J Clin Oncol; 2015 Jun; 45(6):569-75. PubMed ID: 25855621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
    Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
    J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
    Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
    Cohen MH; Johnson JR; Chattopadhyay S; Tang S; Justice R; Sridhara R; Pazdur R
    Oncologist; 2010; 15(12):1344-51. PubMed ID: 21148614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
    Hesketh PJ; Chansky K; Wozniak AJ; Hirsch FR; Spreafico A; Moon J; Mack PC; Marchello BT; Franklin WA; Crowley JJ; Gandara DR
    J Thorac Oncol; 2008 Sep; 3(9):1026-31. PubMed ID: 18758306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
    Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
    Groen HJ; Socinski MA; Grossi F; Juhasz E; Gridelli C; Baas P; Butts CA; Chmielowska E; Usari T; Selaru P; Harmon C; Williams JA; Gao F; Tye L; Chao RC; Blumenschein GR
    Ann Oncol; 2013 Sep; 24(9):2382-9. PubMed ID: 23788751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
    Kubota K; Nishiwaki Y; Tamura T; Nakagawa K; Matsui K; Watanabe K; Hida T; Kawahara M; Katakami N; Takeda K; Yokoyama A; Noda K; Fukuoka M; Saijo N
    J Thorac Oncol; 2008 Dec; 3(12):1439-45. PubMed ID: 19057270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
    Park K; Yu CJ; Kim SW; Lin MC; Sriuranpong V; Tsai CM; Lee JS; Kang JH; Chan KC; Perez-Moreno P; Button P; Ahn MJ; Mok T
    JAMA Oncol; 2016 Mar; 2(3):305-12. PubMed ID: 26720423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
    Yamada K; Takayama K; Kawakami S; Saruwatari K; Morinaga R; Harada T; Aragane N; Nagata S; Kishimoto J; Nakanishi Y; Ichinose Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):629-35. PubMed ID: 23599349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
    Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
    J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
    Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
    Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
    Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
    Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.